Announcements Trials
Browse Landscape

Phase

Phase 3 1

Status

Terminated 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Rectal Neoplasms 2Colonic Neoplasms 2Neoplasms, Glandular and Epithelial 1Neoplasms by Site 1Neoplasms by Histologic Type 1Neoplasms 1Liver Neoplasms 1Liver Diseases 1Digestive System Neoplasms 1Digestive System Diseases 1Carcinoma, Hepatocellular 1Carcinoma 1Adenocarcinoma 1

Interventions

Irinotecan 4Gemcitabine 4130-nm albumin-bound paclitaxel 4napabucasin 3Cyclophosphamide 3Bevacizumab 3Albumin-Bound Paclitaxel 3selpercatinib 2pembrolizumab 2cobimetinib 2Sunitinib 2Sorafenib 2Pemetrexed 2Paclitaxel 2Leucovorin 2Fluorouracil 2Drug Therapy 2Chemoradiotherapy 2Cetuximab 2Aspirin 2Ascorbic Acid 2trametinib 1repotrectinib 1pralsetinib 1osimertinib 1lutetium Lu 177 dotatate 1linifanib 1guadecitabine 1golotimod 1genexol-PM 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Neoplasms by Site × linifanib × Gastrointestinal × Clear all
NCT01009593 2012-09-10

Efficacy and Tolerability of ABT-869 Versus Sorafenib in Advanced Hepatocellular Carcinoma (HCC)

Abbott

Phase 3 Terminated
1,035 enrolled
Gastrointestinal

Adenocarcinoma, Carcinoma, Digestive System Diseases, Digestive System Neoplasms, Carcinoma, Hepatocellular, Liver Diseases, Liver Neoplasms, Neoplasms, Neoplasms by Histologic Type, Neoplasms by Site, Neoplasms, Glandular and Epithelial

Data powered by HemOnc (CC BY 4.0) Colophon âš¡